Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Sell
37
ABVX Quote, Financials, Valuation and Earnings
Last price:
$114.50
Seasonality move
:
19.08%
Day range:
$109.10 - $115.12
52-week range:
$4.77 - $130.25
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.86x
Volume:
1.3M
Avg. volume:
1.4M
1-year change:
1274.67%
Market cap:
$8.9B
Revenue:
--
EPS (TTM):
--
Analysts' Opinion
-
Consensus RatingAbivax SA has received a consensus rating of Buy. The company's average rating is a Buy based on 6 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $125.40, Abivax SA has an estimated upside of 9.51% from its current price of $114.51.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $101.00 representing 11.8% downside risk from its current price of $114.51.
Fair Value
-
According to the consensus of 6 analysts, Abivax SA has 9.51% upside to fair value with a price target of $125.40 per share.
ABVX vs. S&P 500
-
Over the past 5 trading days, Abivax SA has underperformed the S&P 500 by -8.55% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Abivax SA does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Abivax SA has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Abivax SA reported revenues of --.
Earnings Growth
-
Abivax SA has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Abivax SA reported earnings per share of -$0.86.
Enterprise value:
8.9B
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-53.60x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-06-30 | 2024-06-30 | 2025-06-30 | 2024-06-30 | 2025-06-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$693.9K | -$1M | -- | -- | -$284.7K | |
| Operating Income | -$81.7M | -$193.8M | -- | -- | -$54M | |
| EBITDA | -$81M | -$192.8M | -- | -- | -$53.7M | |
| Diluted EPS | -$3.36 | -$3.55 | -- | -- | -$0.87 | |
| Period Ending | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2024-06-30 | 2025-06-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $25.4M | $45.8M | $141.7M | -- | $101.1M | |
| Total Assets | $65.6M | $74.8M | $185.9M | -- | $140.4M | |
| Current Liabilities | $56.8M | $17.4M | $50.2M | -- | $131.9M | |
| Total Liabilities | $62.7M | $68.5M | $98.4M | -- | $197.1M | |
| Total Equity | $2.8M | $6.4M | $87.5M | -- | -$56.7M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-06-30 | 2024-06-30 | 2025-06-30 | 2024-06-30 | 2025-06-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$61.9M | -$167M | -- | -- | -$39.3M | |
| Cash From Investing | -$10.8M | -$229.2K | -- | -- | -$4.2K | |
| Cash From Financing | $170.3M | $287.7M | -- | -- | -$7.7M | |
| Free Cash Flow | -$62.3M | -$167.4M | -- | -- | -- | |
ABVX
Sector
Market Cap
$8.9B
$28.5M
Price % of 52-Week High
87.92%
51.44%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.33%
1-Year Price Total Return
1274.67%
-20.32%
Beta (5-Year)
--
0.520
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$118.70
200-day SMA
Buy
Level
$46.65
Bollinger Bands (100)
Buy
Level
64.29 - 108.59
Chaikin Money Flow
Buy
Level
5.6M
20-day SMA
Sell
Level
$114.64
Relative Strength Index (RSI14)
Buy
Level
54.27
ADX Line
Buy
Level
37.16
Williams %R
Neutral
Level
-67.8595
50-day SMA
Buy
Level
$101.26
MACD (12, 26)
Buy
Level
4.41
25-day Aroon Oscillator
Buy
Level
60
On Balance Volume
Neutral
Level
58.7M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-4.0284)
Sell
CA Score
(Annual)
Level (-3.8445)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (6.2241)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (1)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.
Stock Forecast FAQ
In the current month, ABVX has received 6 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ABVX average analyst price target in the past 3 months is $125.40.
-
Where Will Abivax SA Stock Be In 1 Year?
According to analysts, the consensus estimate is that Abivax SA share price will rise to $125.40 per share over the next 12 months.
-
What Do Analysts Say About Abivax SA?
Analysts are divided on their view about Abivax SA share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Abivax SA is a Sell and believe this share price will drop from its current level to $101.00.
-
What Is Abivax SA's Price Target?
The price target for Abivax SA over the next 1-year time period is forecast to be $125.40 according to 6 Wall Street analysts, 6 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ABVX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Abivax SA is a Buy. 6 of 6 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ABVX?
You can purchase shares of Abivax SA via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Abivax SA shares.
-
What Is The Abivax SA Share Price Today?
Abivax SA was last trading at $114.50 per share. This represents the most recent stock quote for Abivax SA. Yesterday, Abivax SA closed at $114.51 per share.
-
How To Buy Abivax SA Stock Online?
In order to purchase Abivax SA stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get ABVX Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
ABVX
Sector
P/E ratio
--
23.75x
PEG ratio
--
-0.01x
P/B ratio
1.86x
1.83x
Price / LTM sales
--
1.60x
Growth Metrics
ABVX
Sector
Revenue growth
--
4.85%
Earnings growth
--
11.11%
Revenue (5-year growth)
--
6.45%
Earnings forecast
-$0.79
-$0.20
Profitability
ABVX
Sector
Profitability FY 2024
-$1.2M
$3.6M
Return on invested capital
--
-30.98%
Return on assets
--
-27.62%
Return on equity
--
-36.69%
Earnings Date
Last Earnings Date
Sep
8
Next Earnings Date
Mar
23
Estimated Next Earnings Date
Dec
8
Balance Sheet
ABVX
Sector
Total cash
$71.5M
$27.2M
Short term investments
--
$25.7M
Total assets
$212.5M
$79.7M
Long term debt
--
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 6
SMX (Security Matters) Plc [SMX] is up 134.09% over the past day.
Buy
62
PRAX alert for Dec 6
Praxis Precision Medicines, Inc. [PRAX] is up 30.47% over the past day.
Sell
13
PSN alert for Dec 6
Parsons Corp. [PSN] is down 21.1% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
